Taligen takes a tranche

Complement modulation company Taligen Therapeutics Inc. this week was to disclose a $10 million tranche from a $65 million series B round it secured in 2008. Thus far, the company has taken $36 million in four tranches.

Over that time, the company has chosen a new lead candidate. Investor and Chairman Tim Mills of Sanderling Ventures told Ebb & Flow the initial lead candidate, TA106, was an inhaled compound that gave the company proof of concept for selective, controlled complement inhibition by showing the reduction of inflammation in animal airways...